AZD 1744
Alternative Names: AZD1744Latest Information Update: 03 Nov 2008
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Antiasthmatics
- Mechanism of Action CCR3 receptor antagonists; Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 19 Feb 2007 Phase-I clinical trials in Asthma in United Kingdom (unspecified route)